- Page 1 and 2: 2010 Annual Report CIBERDEM Centro
- Page 4 and 5: Letter from the Scientific Director
- Page 6 and 7: Contents Prologue Research results
- Page 8 and 9: Research results Publications In 20
- Page 10 and 11: Project management Introduction The
- Page 12 and 13: Training programme Introduction The
- Page 14 and 15: Outreach activities CIBERDEM Fundra
- Page 16 and 17: More about CIBERDEM The Centro de I
- Page 18 and 19: Human Resources In 2010, CIBERDEM h
- Page 22 and 23: Di@bet.es Study Introduction Attemp
- Page 24 and 25: CIBERDEM Projects Introduction CIBE
- Page 26 and 27: girls (girls born small for gestati
- Page 28 and 29: Biobank Introduction and objectives
- Page 30 and 31: Metabolomics Platform Introduction
- Page 33 and 34: Area 1 Insulin signalling and resis
- Page 35 and 36: Diabetes and cardiovascular Faculta
- Page 37 and 38: Metabolomics Platform Universitat R
- Page 39 and 40: Obesity, inflammation and insulin r
- Page 41 and 42: Mechanisms of control of glucose an
- Page 43 and 44: Metabolic engineering and diabetes
- Page 45 and 46: Molecular mechanisms of insulin res
- Page 47 and 48: Molecular characteristics, and acti
- Page 49 and 50: Heterogenic and polygenic diseases.
- Page 51: Principal Investigator: Antonio Zor
- Page 54 and 55: The research activity of this area
- Page 56 and 57: The cationic cluster of group IVA p
- Page 58 and 59: agent that affects the enterohepati
- Page 60 and 61: Dyslipidaemia, inflammation and end
- Page 62 and 63: Daño orgánico en la diabetes mell
- Page 64 and 65: Proteomic analysis of plasma in the
- Page 66 and 67: Prenatal growth restriction and sub
- Page 68 and 69: The effects of metformin on cardiov
- Page 70 and 71:
Lipids and Arteriosclerosis Researc
- Page 72 and 73:
Review Pitavastatin - from clinical
- Page 74 and 75:
Diabetobe Hospital Clínico San Car
- Page 76 and 77:
Scientific collaborations within CI
- Page 78 and 79:
Atherosclerosis, 209, 201-205 (2010
- Page 80 and 81:
Solvay, SA: 2008-2010 Principal Inv
- Page 82 and 83:
Endocrinology and Nutrition Service
- Page 84 and 85:
Prevención de la Diabetes mellitus
- Page 86 and 87:
Pharmacological targets in inflamma
- Page 88 and 89:
Diabetes and Metabolic Associated D
- Page 90 and 91:
Autonomous Community project Grup d
- Page 92 and 93:
Area 3 of CIBERDEM comprises thirte
- Page 94 and 95:
Escrivá F, Alvarez C J Mol Endocri
- Page 96 and 97:
Am J Physiol Endocrinol Metab, 298,
- Page 98 and 99:
Transgenic animal models and gene t
- Page 100 and 101:
Ayuso E, Mingozzi F, Bosch F Curr G
- Page 102 and 103:
Laboratory of Molecular Endocrinolo
- Page 104 and 105:
Hospital de Cruces Diabetes Researc
- Page 106 and 107:
Research grants International proje
- Page 108 and 109:
Proinsulin and tyrosine hydroxilase
- Page 110 and 111:
Genomic programming of beta cells I
- Page 112 and 113:
Diabetes and obesity: biopathology
- Page 114 and 115:
Utilidad de la ecografía arterial
- Page 116 and 117:
Islet cell and stem cell physiology
- Page 118 and 119:
in diabetic patients with chronic c
- Page 120 and 121:
Liraglutide versus sitagliptin for
- Page 122 and 123:
Unit of Cell Physiology and Nutriti
- Page 124 and 125:
National projects Efectos a corto y
- Page 126 and 127:
Altirriba J, Gasa R, Casas S, Ramí
- Page 128 and 129:
Transcriptional mechanisms of pancr
- Page 131 and 132:
Epilogue
- Page 133 and 134:
Keyword index* Beta-cell signal tra
- Page 135 and 136:
Association of selected ABC gene fa
- Page 137 and 138:
Leiter LA, Levitt NS, Mareev V, Mar
- Page 139 and 140:
Low body adiposity and high leptine
- Page 141 and 142:
Alvaro A, Rosales R, Masana L, Vall
- Page 143 and 144:
The apolipoprotein A5 (APOA5) gene
- Page 145 and 146:
www.ciberdem.org/annualreport CIBER